Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
How did GNTA's recent EPS compare to expectations?
The most recent EPS for Genenta Science SPA is $, expectations of $.
How did Genenta Science SPA GNTA's revenue perform in the last quarter?
Genenta Science SPA revenue for the last quarter is $
What is the revenue estimate for Genenta Science SPA?
According to of Wall street analyst, the revenue estimate of Genenta Science SPA range from $ to $
What's the earning quality score for Genenta Science SPA?
Genenta Science SPA has a earning quality score of B+/44.994537. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Genenta Science SPA report earnings?
Genenta Science SPA next earnings report is expected in
What are Genenta Science SPA's expected earnings?
Genenta Science SPA expected earnings is $, according to wall-street analysts.
Did Genenta Science SPA beat earnings expectations?
Genenta Science SPA recent earnings of $ expectations.